Aktie A0M4KQ YABAO PHARMACEUTICAL GROUP CO., LTD
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Yabao Pharmaceutical Group Co., Ltd

Aktien

A0M4KQ

CNE000001CM5

600351

Schlusskurs Shanghai S.E.
Andere Börsenplätze
 00:00:00 28.05.2024 		% 5 Tage % 1. Jan.
6.33 CNY -1.25% Intraday Chart für Yabao Pharmaceutical Group Co., Ltd -2.76% -8.26%
25.04. Yabao Pharmaceutical Group Co., Ltd. meldet Ergebnis für das erste Quartal zum 31. März 2024 CI
25.04. Yabao Pharmaceutical Group Co., Ltd berichtet über die Ergebnisse für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
Yabao Pharma Gets Nod to Register Asthma Drug Montelukast Sodium Granules
Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 9, 2023.
Yabao Pharmaceutical Group Co., Ltd announces an Increase in Equity Buyback.
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 9, 2023.
Yabao Pharmaceutical Group Co., Ltd(XSSC:600351) added to S&P Global BMI Index
Hunan Caprico Biotechnologies Co., Ltd. announced that it has received funding from Guangzhou Huangpu Biomedical Fund Management Co., Ltd., Yabao Pharmaceutical Group Co., Ltd
Yabao Pharmaceutical Takes Over Rights of Traditional Chinese Medicine for 26 Million Yuan
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 9, 2023.
Yabao Pharmaceutical Group Co., Ltd commences an Equity Buyback Plan for CNY 300 million worth of its shares, under the authorization approved on April 24, 2023.
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
Yabao Pharmaceutical Unit Submits FDA Application for Osteoarthritis Drug
Yabao Pharmaceutical Unit's Sorafenib Tablets Enters US Markets
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022
Fineimmu announced that it has received CNY 100 million in funding from Yabao Pharmaceutical Group Co., Ltd, Panacea Venture Management Co., Ltd. and another investor
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A0M4KQ Aktie
  4. Nachrichten Yabao Pharmaceutical Group Co., Ltd
  5. Andere Sprachen